Form 4: Apimeds Pharmaceuticals US, Inc. Director Kim Christopher Reports Stock Transactions
SEC Form 4 Filing
Director and CMO of Apimeds Pharmaceuticals US, Inc., Christopher Kim, reports the acquisition and disposal of common stock on May 13 and 14, 2025.
Summary
- On May 13, 2025, Christopher Kim, Director and CMO of Apimeds Pharmaceuticals US, Inc., acquired and disposed of 19,770 shares of common stock at a weighted average price of $1.82 per share.
- On May 14, 2025, Kim acquired 7,730 shares at a weighted average price of $1.86 per share, resulting in a total of 27,500 shares beneficially owned.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing stock transactions by a company insider. It doesn't inherently convey positive or negative sentiment.
Industry Context
This Form 4 filing is a routine disclosure required by the SEC for corporate insiders, providing transparency into their trading activities. It does not provide any specific insight into the broader pharmaceutical industry trends.
Stakeholder Impact
- The transactions may be of interest to shareholders as they provide insight into the actions of a key company insider.
Key Dates
| Date | Description |
|---|---|
| 05/13/2025 | Acquisition and disposal of 19,770 shares of common stock at $1.82. |
| 05/14/2025 | Acquisition of 7,730 shares of common stock at $1.86. |
| 05/15/2025 | Date of signature for the Form 4 filing. |
Keywords
Apimeds Pharmaceuticals US, Inc., Christopher Kim, Form 4, stock transactions, common stock, director, CMO
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.